13 results about "Advanced stage" patented technology

A method for performing classification of a severity of at least one liver disease from non-invasive radiographic images is disclosed. The method comprises: providing radiographic images of slices of an abdomen of a patient; pre-processing said radiographic images by: segmenting a liver and a spleen, thus achieving a spleen binary mask and a liver binary mask per slice, and normalizing said images with each other, thus achieving normalized radiographic images per slice; for each slice, from the liver binary mask and said normalized radiographic images, extracting a liver parameter; from at least one spleen binary mask, extracting a spleen parameter; and classifying, in function of both parameters and by help of a trained Machine Learning model, the severity of the at least one liver disease between one among a group of liver disease at early stage and a group of liver disease at advanced stage.

The invention provides a system and a method for detecting applicability of lung cancer immunotherapy. The invention discloses the expression ratio of ARG1 to CXCL13 or the expression ratio of CXCL13 to ARG1 for the first time, and the expression ratio can be used for predicting the applicability of immunotherapy of middle and late stage or advanced stage lung cancer, and has ideal sensitivity. On the basis, the invention also provides a system and a method for detecting the applicability of lung cancer immunotherapy. The invention provides a new scheme for diagnosis of clinical lung cancer immunotherapy applicability.

The application relates to the technical field of biological medicine, and discloses siRNA for inhibiting a P311 gene, a composition and application thereof. The siRNA can specifically knock down P311 gene expression in human tumor cells, can be used as an auxiliary component for improving the drug efficacy of gemcitabine, can improve the drug sensitivity of a pancreatic cancer patient to gemcitabine, can reduce the gemcitabine drug resistance of a pancreatic cancer patient in an advanced stage, can improve the prognosis of the pancreatic cancer patient, can prolong the survival period of the pancreatic cancer patient in the advanced stage, and has important significance for the treatment of pancreatic cancer.

Aspects of the disclosure provide a formulation for treating advanced pancreatic cancer, comprising a combination of a cannabinoid, a terpene, and a flavonoid. To enhance bioavailability and targeted delivery, the formulation is incorporated into a nanoplatform, such as a nanoemulsion, optimizing absorption and delivery to cancer cells. The nanoparticle-based composition specifically targets advanced stages of pancreatic cancer, aiming to inhibit tumor progression and improve clinical outcomes.

The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK1 F137S, activated by G proteins recruited by cone opsin expressed in degenerating cones.

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and / or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and / or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V / VI) and / or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and / or regulated in response to two casein kinase 1 delta inhibitors.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The present invention consists in combining low dose intestinal radiation (ILDR) with immunotherapy or other antineoplastic treatments, in the ideal context of intestinal presence or prevalence of Christensenellaceae family members, especially for solid cancers at an advanced stage (refractory to first line chemo or immunotherapy). The invention also pertains to a bacterial composition,e.g. comprising Chistensenella bacteria, for use in the treatment of cancer in a patient, in combination with intestinal low dose radiotherapy (ILDR) and an antineoplastic treatment.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The invention provides a lung cancer noninvasive screening system and method based on expiration microbiomics, and belongs to the technical field of biomedical detection.The method comprises the steps that a sample is obtained through an expiration collector, a bacteria abundance matrix is generated through a UMI-5R-16S sequencing technology, and the low-biomass expiration microorganism detection rate is remarkably increased; the method comprises the following steps of: constructing three types of hierarchical random forest models: M1 model: healthy human vs. Early lung cancer (I-II stage), and outputting early risk probability based on markers such as Ochrobactrum and the like; m2 model: healthy human vs. Middle and advanced stage lung cancer (III-IV stage), and advanced stage risk probability is output based on Burkholderia and other markers; m3 model: healthy human vs. Full lung cancer (including morning and evening), outputting a comprehensive risk score based on Dietzia and other markers; and M3, primarily screening positive samples, inputting the positive samples into M1 and M2, and performing staging evaluation, wherein a higher risk probability is taken as a criterion during conflict. According to the invention, the total lung cancer primary screening sensitivity is improved, and the early detection rate is increased; the microorganism detection rate of an expiration sample is high; and the single detection cost is lower.

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and / or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and / or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V / VI) and / or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and / or regulated in response to two casein kinase 1 delta inhibitors.

The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo- propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for treating primary biliary cholangitis (PBC) in a subject having advanced stage primary biliary cholangitis (PBC).

This application discloses a method and related equipment for predicting the efficacy of immunotherapy in advanced lung cancer, belonging to the field of deep learning technology. The method includes: acquiring transcriptome sequencing data of the user to be predicted; inputting the transcriptome sequencing data into an immunotherapy efficacy prediction model to obtain an immunotherapy efficacy score output by the model; and determining the predicted immunotherapy efficacy result for the user based on the immunotherapy efficacy score output by the model. The immunotherapy efficacy prediction model is constructed based on the Cox proportional hazards model ridge regression algorithm, the random survival forest algorithm, and the extreme gradient boosting tree algorithm. This application improves the performance and stability of the prediction model by combining these algorithms, thereby enhancing the accuracy of predicting the efficacy of immunotherapy in advanced lung cancer.